O'Shaughnessy Asset Management’s Myriad Genetics MYGN Stock Holding History

O'Shaughnessy Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,216	Closed	-$147K	–	987
2018 Q3	$147K	Sell	3,216 -53	-2%	-$2.36K	﹤0.01%	596
2018 Q2	$121K	Sell	3,269 -1,527	-32%	-$51.6K	﹤0.01%	619
2018 Q1	$142K	Sell	4,796 -1,221	-20%	-$41.3K	﹤0.01%	574
2017 Q4	$207K	Buy	6,017 +3,109	+107%	+$105K	﹤0.01%	526
2017 Q3	$105K	Sell	2,908 -1,720	-37%	-$49.1K	﹤0.01%	625
2017 Q2	$120K	Buy	4,628 +21	+0.5%	+$446	﹤0.01%	603
2017 Q1	$88K	Buy	4,607 +25	+0.5%	+$443	﹤0.01%	637
2016 Q4	$76K	Buy	4,582 +2,803	+158%	+$50.7K	﹤0.01%	671
2016 Q3	$37K	Buy	+1,779	New	+$45.1K	﹤0.01%	711
2015 Q2	–	Sell	-13	Closed	–	–	1056
2015 Q1	$0	Hold	13	–	–	﹤0.01%	1087
2014 Q4	$0	Hold	13	–	–	﹤0.01%	1053
2014 Q3	$1K	Hold	13	–	–	﹤0.01%	945
2014 Q2	$1K	Buy	+13	New	+$484	﹤0.01%	945

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

O'Shaughnessy Asset Management's MYGN Position: Q4 2018 in Review

O'Shaughnessy Asset Management sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 3,216 shares — an estimated $147K sold.

O'Shaughnessy Asset Management first reported a position in MYGN in Q2 2014 and held it in 13 quarters. The position peaked at $207K in Q4 2017. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

O'Shaughnessy Asset Management reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
O'Shaughnessy Asset Management sold 3,216 Myriad Genetics shares in Q4 2018, an estimated $147K.
O'Shaughnessy Asset Management first reported a position in Myriad Genetics in Q2 2014 and held it in 13 quarters.
O'Shaughnessy Asset Management's Myriad Genetics position peaked at $207K in Q4 2017.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.